Related references
Note: Only part of the references are listed.Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors
Rebekka Weber et al.
FRONTIERS IN IMMUNOLOGY (2018)
Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer
L. Castagnoli et al.
ONCOGENE (2017)
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
Gunter von Minckwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Predicting the Efficacy of HER2-Targeted Therapies: A Look at the Host
Martina Di Modica et al.
DISEASE MARKERS (2017)
Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition
Martina Di Modica et al.
ONCOTARGET (2016)
Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to Preoperative Trastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer
Vinay Varadan et al.
CLINICAL CANCER RESEARCH (2016)
Predictive biomarkers in the treatment of HER2-positive breast cancer: an ongoing challenge
Tiziana Triulzi et al.
FUTURE ONCOLOGY (2016)
Trastuzumab Triggers Phagocytic Killing of High HER2 Cancer Cells In Vitro and In Vivo by Interaction with Fcγ Receptors on Macrophages
Yun Shi et al.
JOURNAL OF IMMUNOLOGY (2015)
Natural and therapy-induced immunosurveillance in breast cancer
Guido Kroemer et al.
NATURE MEDICINE (2015)
Robust enumeration of cell subsets from tissue expression profiles
Aaron M. Newman et al.
NATURE METHODS (2015)
Neutrophils in Cancer: Two Sides of the Same Coin
Eileen Uribe-Querol et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2015)
Poly(I:C) and CpG-ODN combined aerosolization to treat lung metastases and counter the immunosuppressive microenvironment
Valentino Le Noci et al.
ONCOIMMUNOLOGY (2015)
Anti-HER2 CD4+ T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer
Jashodeep Datta et al.
BREAST CANCER RESEARCH (2015)
Prospective neoadjuvant analysis of PET imaging and mechanisms of resistance to Trastuzumab shows role of HIF1 and autophagy
M. I. Koukourakis et al.
BRITISH JOURNAL OF CANCER (2014)
Activated d16HER2 Homodimers and SRC Kinase Mediate Optimal Efficacy for Trastuzumab
Lorenzo Castagnoli et al.
CANCER RESEARCH (2014)
PDGFRβ and FGFR2 mediate endothelial cell differentiation capability of triple negative breast carcinoma cells
Ilaria Plantamura et al.
MOLECULAR ONCOLOGY (2014)
Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2
Carla De Giovanni et al.
BREAST CANCER RESEARCH (2014)
Neutrophils mediate antibody-induced antitumor effects in mice
Marcello Albanesi et al.
BLOOD (2013)
Effective Anti-Neu-Initiated Antitumor Responses Require the Complex Role of CD4+ T Cells
Eric D. Mortenson et al.
CLINICAL CANCER RESEARCH (2013)
Activity and resistance of trastuzumab according to different clinical settings
Elda Tagliabue et al.
CANCER TREATMENT REVIEWS (2012)
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
Luca Gianni et al.
LANCET ONCOLOGY (2012)
Tumor-associated macrophages in breast cancer: distinct subsets, distinct functions
Damya Laoui et al.
INTERNATIONAL JOURNAL OF DEVELOPMENTAL BIOLOGY (2011)
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
Dennis Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy
John Stagg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity
SaeGwang Park et al.
CANCER CELL (2010)
Arginase: an emerging key player in the mammalian immune system
Markus Munder
BRITISH JOURNAL OF PHARMACOLOGY (2009)
T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers
Achim Rody et al.
BREAST CANCER RESEARCH (2009)
Quantitative expression profiling of highly degraded RNA from formalin-fixed, paraffin-embedded breast tumor biopsies by oligonucleotide microarrays
Maria Ravo et al.
LABORATORY INVESTIGATION (2008)
Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?
L Arnould et al.
BRITISH JOURNAL OF CANCER (2006)
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
A Subramanian et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Neoadjuvant trastuzumab induces apoptosis in primary breast cancers
SK Mohsin et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
The macrophage and the apoptotic cell: an innate immune interaction viewed simplistically?
CD Gregory et al.
IMMUNOLOGY (2004)
Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2
R Gennari et al.
CLINICAL CANCER RESEARCH (2004)
Share Paper
